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Advancing the public health applications of 
Chlamydia trachomatis serology
Sarah C Woodhall, Rachel J Gorwitz, Stephanie J Migchelsen, Sami L Gottlieb, Patrick J Horner, William M Geisler, Catherine Winstanley, Katrin Hufnagel, 
Tim Waterboer, Diana L Martin, Wilhelmina M Huston, Charlotte A Gaydos, Carolyn Deal, Magnus Unemo, J Kevin Dunbar, Kyle Bernstein
Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is 
caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New 
serological assays for Chlamydia trachomatis could facilitate improved understanding of C trachomatis epidemiology 
and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and 
might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological 
assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions 
including screening and treatment, and to assess new vaccine candidates. However, questions about the performance 
characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance 
development within this field. In this Personal View, we explore the available information about C trachomatis serology 
and propose several priority actions. These actions involve development of target product profiles to guide assay 
selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate 
assay development and evaluation, and development of technical and statistical methods for assay evaluation and 
analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public 
health community to align technological developments with their potential applications.
Introduction
Chlamydia trachomatis is an obligate intracellular 
bacterium that can cause both genital and ocular 
infections. Genital C trachomatis infection is the most 
common, curable STI worldwide, with an estimated 131 
million new cases each year.1 Most infections are 
asymptomatic, but if left untreated can cause scarring of 
the upper reproductive tract in women and lead to 
serious complications in women, including pelvic 
inflammatory disease, ectopic pregnancy, and tubal 
infertility.2 Trachoma is caused by ocular infection with C 
trachomatis and is the leading infectious cause of 
blindness worldwide.3 WHO estimates that around 190 
million people are at risk of blindness from trachoma, 
with most of these people living in Africa. There has 
been substantial investment in the past decade in public 
health programmes to control both genital and ocular 
infection due to C trachomatis. Control efforts for genital 
chlamydia have largely focused on enhanced detection 
and treatment of C trachomatis among young adults, and 
for trachoma control efforts have focused on improved 
access to water, sanitation, and hygiene, and mass drug 
administration with azithromycin in affected 
communities.3 However, several important questions 
remain about C trachomatis epidemiology, the most 
effective means of control, and optimal models of 
surveillance.4–6 Given the ongoing control efforts and the 
promise of new C trachomatis vaccines,7 robust methods 
are needed to allow monitoring of and insight into the 
prevalence and incidence of chlamydia infection,8 and 
the progression to scarring sequelae. Measures of current 
infection based on DNA or RNA detection (ie, using 
nucleic acid amplification tests) provide an inadequate 
understanding of these features of C trachomatis 
infection. Therefore, alternative approaches are required, 
and in recent years interest in the use of serological 
assays within the fields of genital chlamydia and 
trachoma has been increasing.
Methods to detect C trachomatis antibodies in serum 
have been available for several decades.9 However, use of 
serological assays has been limited by C trachomatis’ cross-
reactivity with other Chlamydia spp,10 suboptimal sensitivity 
of many assays,11,12 an incomplete underst`anding about 
the longevity and clinical implications of C trachomatis 
antibodies, and the relationship between C trachomatis 
infection and antibody response.11 Consequently, the 
widespread use of chlamydia seroepidemiology decreased 
among researchers for several years, as did funding. 
Following the development of novel, sensitive, and more 
specific C trachomatis serological assays,13–17 there is now 
growing interest in the use of these assays as an 
epidemiological tool. For example, assays have been 
developed with the capability to detect antibodies against a 
range of C trachomatis antigens, lateral flow assays are 
being evaluated for field use, and dried blood spots have 
been used to facilitate specimen collection, transport, and 
storage (table 1).
The current understanding of mucosal immunity and 
C trachomatis immunology suggests that urogenital and 
ocular infections with C trachomatis lead to detectable 
IgG response with use of appropriate serological assays 
in most confirmed infections.13–15,23 Several factors affect 
the magnitude of IgG response and the ability of 
serological assays to detect a previous C trachomatis 
infection, including the target antibody, assay used, time 
since infection, and patient characteristics such as age, 
sex, race, and the number of previous C trachomatis 
infections.13,14,16,58 In a UK-based study13,15 that compared 
several assays in the same population, the sensitivity to 
detect a previous known chlamydia infection ranged 
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from 46% (IgG pELISA plus medac assay, medac, Wedel, 
Germany) to 83% (Pgp3 double-antigen) in women and 
40% (SeroCT; Savyon Diagnostics, Ashdod, Israel) to 
54% (Pgp3 double-antigen) in men when compared with 
a previous C trachomatis diagnosis by nucleic acid 
amplification tests. Seroreversion (ie, loss of detectable 
antibodies) has been shown in some cases but varies by 
infection history and assay,58 with minimal loss of 
detectable antibody reported in one study using a Pgp3 
double-antigen ELISA.15 In a study59 of C trachomatis 
seroprevalence in the context of mass azithromycin 
treatment for trachoma prevention in a high prevalence 
area, no instances of seroreversion were observed after 
6 months. C trachomatis serological assays can therefore 
be used to measure age-specific cumulative incidence,11,18 
despite representing a lower bound estimate due to 
potentially incomplete seroconversion and loss of 
detectable antibodies over time. C trachomatis antibody 
response has also been found to correlate with a known 
history of scarring sequelae. For example, titres of C 
trachomatis antibodies have been found to be higher in 
women with tubal factor infertility than in women 
without this disease and some specific antibodies have 
been found to be more common in women with known 
disease than in those without disease.47 Thus, serological 
assays might be used as a potential biomarker of disease.
Platform or format Antigens detected (antibody class or subclass) Examples of public health applications
Measure 
seroprevalence 
or estimate 
incidence
Investigate 
association 
with disease
Evaluate control 
interventions
Genital 
Chlamydia 
trachomatis
Trachoma
ELISAs 
Wills et al13 Indirect ELISA Pgp3 (IgG) 18 ·· 18 ··
Geisler et al14 Indirect ELISA Elementary bodies from Chlamydia trachomatis serovars 
D/UW-3, F/ICCal-13, and J/UW-36 (IgG1, IgG3)
14,19  20,21 ·· ··
Horner et al15 Double-antigen ELISA Pgp3 (IgG, IgA, IgM) 15,18,22 ·· 18 ··
Winstanley et al16 Indirect ELISA Pgp3 (IgG) ·· ·· ·· ··
Albritton et al23 Indirect ELISA Elementary bodies from Chlamydia trachomatis serovars 
D/UW3/Cx and E/UW5/Cx (IgG, IgA)
·· 23 ·· ··
Migchelsen et al24 Indirect ELISA on dried blood spots Pgp3 (IgG) 24, 25 ·· ·· ··
Menon et al26 Multi-peptide indirect ELISA 12-mer peptides derived from HtrA, hsp60, and Ct44327 (IgG) ·· 26,28 ·· ··
Commercially available* ELISA or EIA MOMP and hsp60 (IgG, IgA) 29,30,31 32,21, 33–39 ·· ··
Multiplex bead arrays
Goodhew et al17 Multiplex bead array Pgp3 and CT694 (IgG, IgA) 17 ·· ·· 40–42,43
Willhauck-Fleckenstein et al44 Multiplex bead array MOMP A/D/L2, PorB, TARP, hsp60-1, and Pgp3 (IgG, or IgG, 
IgA, IgM)
·· ·· ·· ··
Near-patient testing
Gwyn et al45 Lateral flow Pgp3 (IgG, IgA, IgM) 45,46 ·· ·· ··
Whole proteome microarray
Budrys et al47 ELISA-based proteome array Representing 908 proteins of Chlamydia trachomatis strain 
D/UW-3/Cx (IgG)
·· 47 ·· ··
Lu et al48 Whole proteome microarray Representing 908 genomic and plasmid open reading 
frames of Chlamydia trachomatis strain D/UW3 (IgG, IgA, 
IgM)
·· 48,49 ·· ··
Hufnagel et al50 Whole proteome microarray Representing 895 proteins of Chlamydia trachomatis strain 
D/UW-3/Cx (IgG, or IgG, IgA, IgM)
·· 50 ·· ··
Immunofluorescence
Chernesky et al51 Whole-cell inclusion 
immunofluorescence
L2 serovar (IgG, IgA, IgM) ·· 52,53 ·· ··
Commercially available† Micro-immunofluorescent assay Elementary bodies from Chlamydia trachomatis serovars 
D-K (IgG, IgA, IgM)
·· 54 ·· ··
Wang55 Modified micro-immunofluorescent 
assay protocol
Elementary bodies from Chlamydia trachomatis (IgG) 56 57 ·· ··
This table is not intended to be a comprehensive review. ELISA=enzyme-linked immunosorbent assays. HtrA=high temperature requirement A protease. hsp60=heat shock protein 60. EIA=enzyme 
immunoassay. MOMP=major outer membrane protein. TARP=translocated actin-recruiting phosphoprotein. *Chlamydien IgG rELISA medac assay, medac, Wedel, Germany; Chlamydia trachomatis EIA assay kit, 
Pathtech, Melbourne, Australia; and SeroCT RT kit, Savyon Diagnostics, Ashdod, Israel. † Chlamydia MIF IgG, Focus Diagnostics, Cypress, USA and SeroFIA, Savyon Diagnostics, Ashdod, Israel.
Table 1: Chlamydia trachomatis serological assays and examples of their public health applications to date
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Because the sensitivity of serological assays is 
inadequate, C trachomatis serology has limited diagnostic 
value; in the absence of genetic diagnostic methods it is 
an accepted tool for presumptive diagnosis of 
lymphogranuloma venereum,60 but it is not used for 
diagnosis of other biovars. Instead, C trachomatis 
serological assays have a potential role in monitoring and 
surveillance by providing a measure of history of C 
trachomatis exposure among individuals tested. When 
applied to appropriate samples, such measures might be 
useful to inform resource allocation and possible clinical 
need by indicating the size of the population affected, 
and the effect of population-based interventions such as 
screening or mass drug administration.
Therefore in this Personal View, we explore the 
potential public health applications of C trachomatis 
serology, discuss key challenges of its use, and finally 
propose priorities for research and development that 
might help advance the field of C trachomatis control. 
This work grew out of an expert meeting convened by 
Public Health England in September, 2016 (The Public 
Health applications of Chlamydia trachomatis serology; 
London, UK), and subsequent discussions of studies 
relating to different assays presented at the 2016 
European Society for Chlamydia Research meeting 
(Oxford, Sept 6–9, 2016). 
Public health applications of Chlamydia trachomatis 
serology
C trachomatis serology provides a means of quantifying 
the prevalence and incidence of chlamydia infection. A 
thorough understanding of population-level C trachomatis 
prevalence and incidence is crucial to identify unmet 
needs for screening and treatment services and to 
evaluate the impact of C trachomatis control interventions. 
However, obtaining reliable estimates of C trachomatis 
prevalence and incidence is challenging. In the case of 
genital chlamydia, most C trachomatis infections are 
asymptomatic, so an increase in screening would lead 
to an increase in reported diagnoses.61 As a result, 
surveillance is often centred on only case-based reporting, 
with scarce information about numbers of patients 
tested, resulting in an underestimate of the true 
incidence of C trachomatis infection.61 Furthermore, 
comparability of surveillance data between countries is 
limited by differences in testing recommendations, 
performance characteristics of diagnostic tests, and 
reporting policies and practices.62 Even when the total 
number of people tested in a given country is known, 
interpreting estimates of the proportion of people who 
test positive for chlamydia infection is difficult, because 
the tested population has a different underlying risk 
from the general population. Therefore, the proportion 
testing positive will often present a biased measure of 
prevalence.61,63 Few countries have undertaken surveys of 
prevalence in samples of the general population, and 
when they have been done,64–66 the surveys were resource 
intensive and unlikely to be feasible in many countries, 
because of the costs involved.
C trachomatis seroprevalence as a marker of 
cumulative incidence has been used in several 
countries15,18,22,29,30,67 to assess C trachomatis epidemiology, 
and in some cases to investigate population effect of 
control interventions. In the field of trachoma, mass 
drug administration programmes have been successful 
in reducing C trachomatis infection and C trachomatis-
related ocular disease.24,68,69 Longitudinal C trachomatis 
serology monitoring has strong potential as a tool for 
post-elimination surveillance,40–42 and so provides an 
opportunity to evaluate programme effectiveness and 
possibly a further understanding of the public health 
response needed in countries where trachoma has not 
been eliminated.70 Subject to certain assumptions about 
the population sampled, C trachomatis  incidence can be 
estimated from repeated, cross-sectional C trachomatis 
seroprevalence surveys,71 although it would be necessary 
to adjust for imperfect assay sensitivity and specificity 
(Ades AE, personal communication). C trachomatis 
serology can also be used to detect step changes in 
exposures by birth cohort, which would be expected in 
the context of control measures.40,72 Distinguishing 
between recent and past or long-standing infections 
would also help determine the incidence of disease, and 
methods are already being developed to enable 
C trachomatis serology to be used for this purpose.73
Another potential application of C trachomatis serology 
is as a measure of diseases related to chlamydia 
infections, such as pelvic inflammatory disease or ectopic 
pregnancy. Because the end goal of C trachomatis control 
is to reduce the incidence of disease, monitoring of 
disease biomarkers and not just of infection might 
improve understanding of whether C trachomatis control 
is leading to a reduction in reproductive sequelae, even 
in the absence of substantial reductions in transmission. 
A C trachomatis-specific biomarker of disease would 
be particularly useful, because C trachomatis-related 
diseases might occur many years after the causative 
infection and C trachomatis is not the only cause of 
long-term reproductive complications such as pelvic 
inflammatory disease, ectopic pregnancy, and tubal 
factor infertility.2 Measures of the proportion of long-term 
sequelae that are attributable to C trachomatis infection 
(the so-called population excess fraction) are also 
essential to determine the need for and cost effectiveness 
of control interventions.
Serological methods have been used to investigate 
the relationship between C trachomatis infection and 
sequelae as well as to estimate the proportion of 
long-term sequelae attributable to genital C trachomatis 
infection.20,21,32,52,74 Novel approaches also offer some 
promise in this area; for example, Ades and colleagues52 
have developed a method using finite mixture modelling 
of antibody titre to estimate the population excess 
fraction of tubal factor infertility caused by chlamydia 
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infection. Additionally, proteomic arrays are also being 
assessed as a means of identifying serological fingerprints 
to indicate the presence of disease related to genital 
C trachomatis infection50 and scarring following ocular 
infection.49
Another potential application of C trachomatis serology 
is development and evaluation of C trachomatis vaccines. 
The joint WHO and National Institutes of Health (NIH) 
sexually transmitted infection vaccine roadmap75 has set 
out the need for an effective C trachomatis vaccine. 
Substantial progress towards this vaccine has been made 
in recent years, with candidate vaccines now in the 
preclinical and clinical testing phases.7 Several priority 
action areas set out in the WHO and NIH roadmap 
might be addressed through the development and 
application of serological assays. This includes using 
serological assays to obtain better epidemiological data, 
improve understanding of the natural history of 
C trachomatis and burden of sequelae, and expedite 
clinical development and evaluation of candidate 
vaccines, thereby encouraging investment in 
C trachomatis vaccine development. Specifically, if acting 
as biomarkers for disease C trachomatis serological assays 
could be used to obtain more complete and precise 
estimates of the global burden of C trachomatis-associated 
sequelae, which are important for establishing the public 
health rationale for vaccination and for potential 
investors to assess the possible effect of investing in any 
successful vaccine candidate.7
When a safe vaccine candidate does enter a 
phase 3 clinical trial, C trachomatis serology could help 
identify C trachomatis-naive participants for recruitment, 
and help develop vaccination strategies through an 
understanding of age-specific exposure. Vaccine 
evaluation would also benefit from a biomarker of tubal 
damage for use as part of a clinical endpoint for 
assessing vaccine efficacy, because of the current 
diagnostic inaccuracy for C trachomatis-related outcomes 
such as pelvic inflammatory disease.2 The time and 
resources needed for a clinical trial of candidate 
C trachomatis vaccines with pelvic inflammatory disease 
or tubal factor infertility as outcomes might also be 
prohibitive. It is unclear whether serology will be able to 
provide such a biomarker of tubal damage, and 
serological methods might need to be used in 
combinaton with cellular markers or radiological 
findings. However, serology is an important area of 
research given the need for such measures in any future 
vaccine evaluation. Because C trachomatis infections 
(with the exception of lymphogranuloma venereum) are 
localised in the columnar epithelium, detection of 
antibodies from genital secretions has been proposed as 
a means of investigating correlates of immune protection 
against C trachomatis,23 which might complement 
serological investigations. Assessment of vaccine-
induced immune responses will depend on the vaccine’s 
mechanism of action. Assays that distinguish between 
the natural and vaccine-induced antibody response will 
therefore be needed.
Key challenges to the use of Chlamydia trachomatis 
serology in public health
Although progress has been made in recent years, some 
important challenges remain within the field of 
C trachomatis serology that need to be addressed to 
improve the use and value of new serological assays in a 
public health context. Interpretation of C trachomatis 
seroprevalence is difficult; several complexities exist 
and include the following: not everyone exposed to 
C trachomatis will become infected, some individuals 
with this infection might not develop antibodies, 
women are more likely to develop detectable antibodies 
than men following urogenital C trachomatis 
infection,13,18,76 C trachomatis antibodies are not specific 
to the infection site (ie, ocular or urogenital), and 
seroprevalence can vary with the number of previous 
infections and time since infection as antibodies 
develop or wane.58 These complexities require careful 
consideration when planning studies and doing 
statistical analyses.
Determining assay sensitivity and specificity in the 
absence of universal guidelines is also challenging. The 
population that will be tested should be carefully 
considered when selecting positive and negative controls 
(ie, those with or without infection or disease) and setting 
assay thresholds. For example, a study aimed at 
investigating C trachomatis infection might need a 
different definition of positive and negative controls than 
a study aimed at investigating C trachomatis-associated 
disease. A further challenge involves the choice of 
thresholds that define C trachomatis antibody response in 
different populations, because serological assays might 
be affected by differences in cross-reactivity and 
background antibody concentrations, which can vary for 
example by country or ethnicity, or both.
The relative performance of different tests cannot 
easily be determined without evaluation against the same 
reference sera. Some laboratory-developed assays have 
been compared with commercial assays or other 
laboratory-developed assays,13,15,45,46 but there are few data 
available to show how different assays perform within 
the same population. To establish performance 
characteristics of C trachomatis serological assays for 
different applications and populations, large numbers of 
serum samples linked to well characterised clinical and 
demographical information are needed. Serum samples 
from previous studies (eg, human papillomavirus 
vaccine trials77 and HIV unlinked anonymous testing78) or 
residual samples from clinical testing67 could be used, 
but they often have limited clinical or demographical 
information, and varying access arrangements mean that 
assays have not been evaluated on comparable samples.
Optimal test characteristics might vary between 
different applications of C trachomatis serology, 
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suggesting that different characteristics might be 
prioritised. For example, a test to measure whether 
someone has had C trachomatis infection will need to 
detect antibodies that persist over time at relatively low 
concentrations with high specificity. However, a test that 
is used to estimate the population excess fraction would 
ideally be able to distinguish between complicated and 
uncomplicated C trachomatis infections (eg, by identifying 
high versus low concentrations of antibody in serum,52 
the antibody subclass,14 or antibodies specifically 
associated with complications47).
Similarly, the context in which an assay is to be 
deployed will influence prioritisation. For example, in a 
research setting, tests could be more operator-intensive 
and less cost-effective than tests used for ongoing 
surveillance given limited government budgets. Further-
more, a test requiring high volume of sera might be 
acceptable in a setting where additional blood can be 
collected from consenting patients, whereas surveillance 
systems relying on leftover sera from routine testing 
might have an inadequate volume available. Applications 
of C trachomatis serological assays in a surveillance 
context might be more tolerant to some reduced precision 
than when used within a vaccine trial, where previous 
infection needs to be ruled out to precisely define 
populations for inclusion in any efficacy analysis. 
Priority actions for research and development
To address these challenges, we suggest three priority 
actions for research and development (panel). 
Generating target product profiles
Target product profiles originated in the field of drug 
development to focus discussions between regulatory 
authorities and research sponsors. They allow the drug 
development process to be directed with the end goal in 
mind, so that both patient and market needs are met.79 
The process of establishing target product profiles is 
now commonly used in drug and vaccine development 
and their use has also extended into the field of 
diagnostics—eg, for tuberculosis80 and point-of-care 
diagnostics for sexually transmitted infections.81 Target 
product profiles for C trachomatis serological assays 
should establish the minimal and optimal assay 
requirements for the different applications previously 
described. Table 2 sets out some of the initial 
considerations that can be used to inform target product 
profiles. A target product profile requires broad 
technical consultation across clinical, microbiological, 
and epidemiological fields, as well as representation 
from vaccine and diagnostic development companies, 
research groups, public health agencies, and funders.
Establishing a serum bank
A well defined serum bank focused on the evaluation of 
C trachomatis serology will be an invaluable resource. 
The value of serum banks in research of infectious 
diseases was recently set out in an Editorial82 in 
The Lancet, which highlighted the role serological studies 
could play in understanding worldwide distribution of 
disease and argued for the establishment of a World 
Serology Bank. The development of a C trachomatis-
specific serum bank would enable clear and fair access to 
specimens and relevant epidemiological and clinical data 
(eg, age, sex, and a history of C trachomatis diagnosis). 
A serum bank would have the potential to support the 
development and evaluation of serological assays, and to 
facilitate identification of potential vaccine targets and 
correlates of protection. The bank should include sera 
from women and men of a variety of countries, ages, and 
ethnicities. These individuals would also have a range 
of characteristics that include varying histories of 
C trachomatis diagnosis, incorporating different times 
since treatment and different numbers of known 
infections; those with and without reproductive 
complications; and those exposed to potentially 
cross-reactive pathogens such as Chlamydia pneumoniae. 
Panel: Priority actions to further develop the public health applications of Chlamydia 
trachomatis serological assays
Generate target product profiles for C trachomatis serological assays
• What are the minimal or optimal characteristics of C trachomatis serological assays 
for different purposes (eg, design and evaluation of genital C trachomatis control 
programmes, design and evaluation of trachoma or ocular C trachomatis control 
programmes, or vaccine development and evaluation) and measures 
(eg, seroprevalence of C trachomatis antibodies as a measure of prevalence and 
incidence, measure of population excess fraction of disease such as pelvic 
inflammatory disease or tubal factor infertility, biomarker of disease either alone or 
in combination with other measures, measure of being C trachomatis-naive, or 
measure of vaccine-induced immune response)?
• What are the minimal or optimal characteristics of the aforementioned purposes and 
measures in different countries?
Establish a serum bank
• Adequate volumes of well characterised serum samples from individuals who have 
had C trachomatis infection and sera from those who have not had this infection 
should be included. Samples should be stored from individuals of a variety of ages and 
ethnicities, including children who might still have the maternal antibody, with 
different characteristics including the numbers of known infections, time since 
treatment, and presence of known reproductive tract or ocular complications.
• Standardised assessments of clinical outcome and epidemiological data should be 
incorporated
• The serum bank should be established with appropriate access arrangements.
Develop methods for assay evaluation and analysis of serological findings
• Define how sensitivity and specificity be estimated for different purposes
• Define how positive and negative controls should be selected for different test 
applications?
• Better understand what thresholds should be used for each assay for different 
applications or test settings
• Define how head-to-head comparison studies be done
• Explore and assess what statistical methods should be used to measure epidemiological 
parameters (eg, incidence of infection and population excess fraction)?
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Some applications of C trachomatis serology, such as the 
identification of biomarkers of scarring sequelae or 
developing serological assays to distinguish between 
infection and exposure, might also benefit from 
simultaneous assessment of cellular immunity. 
Therefore, collections that incorporate both serum and 
whole blood specimens would be particularly valuable, 
although it would require different regulatory 
permissions in some settings and would incur additional 
expenses for collection and storage arrangements.
Developing methods for assay evaluation and analysis
Shared protocols to guide assay evaluation would allow 
for comparability of estimates with use of C trachomatis 
serological methods across assays and increase 
consistency of reporting. Evaluation protocols should 
incorporate a consensus position on optimum methods 
of estimating sensitivity and specificity of C trachomatis 
serological assays, and recognise the need for selection 
of controls and assay thresholds to be determined 
according to the intended application while also 
considering the potential for cross-reactivity. Future 
efforts should also focus on development and 
application of statistical methods to appropriately 
analyse C trachomatis serological findings.
Conclusions
As the reported incidence of reported cases of C trachomatis 
infection remains high or continues to increase in many 
developed countries, the use of C trachomatis serology in 
several areas of public health is likely to be effective, and 
has already provided further insight into C trachomatis 
epidemiology and natural history. We explored the 
available information about C trachomatis serology and 
identified three priority actions that we believe would 
directly benefit public health and advance knowledge 
within the C trachomatis field.
As public health agencies continue to address the high 
rates of C trachomatis infection and the con siderable 
morbidity that arises as a result, a more data-driven 
approach to programmatic decision making at the country, 
state, and municipality level is essential. Promising 
interventions, including vaccines, do and will need robust 
measures for estimating the population at risk and for 
determining the potential effect of prevention measures. 
C trachomatis serology is a promising additional tool for 
public health that could help improve the understanding 
of the populations at risk and could support the 
development of novel and effective interventions.
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